Sil­ver­back Ther­a­peu­tics gets $78M boost to 'recon­cep­tu­al­ize' an­ti­body-drug con­ju­gates

The resur­gence of an­ti­body-drug con­ju­gates (AD­Cs), in which a can­cer-killing tox­in is at­tached to a spe­cif­ic an­ti­body us­ing a biodegrad­able link­er, has of­fered the thriv­ing field of on­col­o­gy an­oth­er po­tent weapon in the fight against can­cer. But what if this tro­jan horse tech­nol­o­gy could be tweaked to link im­mune-stim­u­la­to­ry agents — as op­posed to cy­to­tox­ic pay­loads — to mon­o­clon­al an­ti­bod­ies?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.